Core Viewpoint - KORE Group Holdings, Inc. is under investigation by the Schall Law Firm for potential breaches of fiduciary duty by its directors and management, following a merger announcement valued at approximately $726 million [1][1]. Group 1: Investigation Details - The Schall Law Firm is investigating claims on behalf of KORE investors regarding possible breaches of fiduciary duty by the company's board [1]. - The investigation is focused on whether the KORE board acted in the best interests of shareholders during the merger process [1]. Group 2: Merger Announcement - KORE announced on February 27, 2026, that it has entered into a definitive agreement for a merger, where Searchlight and Abry will acquire all outstanding shares of KORE not currently owned by them [1]. - The all-cash transaction is valued at approximately $726 million, with shareholders set to receive $9.25 per share [1].

Core Viewpoint - A class action lawsuit has been filed against Navan, Inc. (NAVN) for alleged securities fraud related to its initial public offering (IPO) on October 31, 2025, where approximately 36.9 million shares were sold at $25.00 per share [1] Group 1: Lawsuit Details - The lawsuit claims that the Registration Statement issued during the IPO contained materially false and misleading statements and failed to disclose adverse facts about the company's business and operations [1] - Investors have until April 24, 2026, to file a lead plaintiff motion in the ongoing class action [1] Group 2: Financial Performance - Navan reported a significant increase in sales and marketing expenses, which rose to nearly $95 million, a 39% increase from $68.5 million in the previous quarter [1] - Following the announcement of the financial results and the resignation of the CFO, Navan's stock price dropped by $1.74, or 11.9%, closing at $12.90 per share on December 16, 2025 [1] - The stock has continued to decline, trading as low as $9.20 per share, representing a decrease of over 63% from its IPO price [1]

Core Insights - Navan, Inc. (NAVN) is facing a class action lawsuit due to alleged securities fraud related to its IPO on October 31, 2025, where it sold approximately 36.9 million shares at $25.00 each [1] - The lawsuit claims that the Registration Statement contained materially false and misleading statements and failed to disclose significant adverse facts about the company's business and operations [1] Financial Performance - Following the IPO, Navan reported a significant increase in sales and marketing expenses, rising to nearly $95 million, a 39% increase from the previous quarter's $68.5 million [1] - The company's stock price fell by $1.74, or 11.9%, closing at $12.90 per share on December 16, 2025, and has since dropped to as low as $9.20, representing over a 63% decline from the IPO price [1] Legal Proceedings - Investors who purchased Navan common stock in connection with the IPO are encouraged to file a lead plaintiff motion by April 24, 2026, to participate in the class action lawsuit [1] - The lawsuit alleges that the company misled investors regarding its financial health and operational prospects, particularly concerning the increased sales and marketing expenses necessary to sustain growth [1]

Core Viewpoint - The article discusses a class action lawsuit against uniQure N.V. related to alleged securities fraud, with a deadline for investors to seek lead plaintiff status by April 13, 2026 [1]. Summary by Sections Lawsuit Details - The lawsuit is on behalf of investors who purchased uniQure securities between September 24, 2025, and October 31, 2025 [1]. - Allegations include that the design of uniQure's Pivotal Study was not fully approved by the FDA and that the company downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline due to additional studies [1]. Company Disclosure - On November 3, 2025, uniQure disclosed that the FDA no longer agreed that data from Phase I/II studies of AMT-130 would be adequate for BLA submission, leading to uncertainty regarding the BLA submission timeline [1]. - Following this disclosure, uniQure's share price fell by $33.40, approximately 49.33%, from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [1].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit against Oracle Corporation, alleging that the company misled investors regarding its business operations and financial health during the specified class period from June 12, 2025, to December 16, 2025 [1] Allegations - The lawsuit claims that Oracle's AI infrastructure strategy would lead to significant increases in capital expenditures (CapEx) without corresponding near-term revenue growth [1] - It is alleged that Oracle's increased spending poses serious risks to its debt and credit rating, free cash flow, and ability to fund projects [1] - The representations made by Oracle regarding its business operations and prospects are claimed to be materially false and misleading, lacking a reasonable basis [1] Legal Proceedings - Shareholders interested in participating as lead plaintiffs must file motions with the court by April 6, 2026 [1] - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [1] Rosen Law Firm Background - Rosen Law Firm is recognized for its focus on shareholder rights litigation and has successfully recovered over $1 billion for shareholders since its inception [1]

Core Viewpoint - Inovio Pharmaceuticals, Inc. is facing a class action lawsuit due to alleged securities fraud, with a deadline for shareholders to file a lead plaintiff motion by April 7, 2026. The lawsuit claims that the company made misleading statements regarding its product development and regulatory prospects, leading to significant stock price declines [1]. Summary by Relevant Sections Company Performance - Inovio's stock price fell by $0.27 (3.1%) to close at $8.44 per share on August 9, 2024, following the announcement of a delay in submitting the Biologics License Application (BLA) for INO-3107 due to manufacturing issues [1]. - On December 29, 2025, the stock price dropped by $0.56 (24.45%) to close at $1.73 per share after the FDA accepted the INO-3107 BLA on a standard review timeline instead of the anticipated accelerated review [1]. Legal Proceedings - The class action lawsuit alleges that Inovio's management made materially false and misleading statements and failed to disclose adverse facts about the company's operations and prospects during the class period from October 10, 2023, to December 26, 2025 [1]. - Specific allegations include deficiencies in the manufacturing of Inovio's CELLECTRA device, the unlikelihood of timely BLA submission, and overstated regulatory and commercial prospects for INO-3107 [1]. Investor Actions - Shareholders who suffered losses during the class period are encouraged to contact Glancy Prongay Wolke & Rotter LLP to potentially pursue claims under federal securities laws [1].

Core Viewpoint - Enphase Energy, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between April 22, 2025, and October 28, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Enphase and certain executives failed to disclose material information, violating federal securities laws [1] - Allegations include overstating the company's ability to manage channel inventory and offset impacts from the termination of the Residential Clean Energy Credit [1] - The case is identified as Tripathi v. Enphase Energy, Inc., No. 26-cv-01380 [1] Group 2: Investor Actions - Investors who suffered losses during the specified period have until April 20, 2026, to request appointment as lead plaintiff [1] - Participation in any recovery does not require serving as a lead plaintiff [1] Group 3: Law Firm Background - Kahn Swick & Foti, LLC is a prominent boutique securities litigation law firm, ranked among the top 10 firms nationally based on total settlement value [1] - The firm represents a variety of clients, including public and private institutional investors, in seeking recoveries for investment losses due to corporate fraud [1]

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims for Grail, Inc. investors regarding losses that may be recoverable under federal securities laws following the company's failure to meet clinical trial endpoints [1][1]. Group 1: Investigation Details - The investigation focuses on Grail's executive officers and their compliance with federal securities laws [1]. - Grail disclosed on February 19, 2026, that its NHS-Galleri trial did not achieve its primary clinical endpoint, leading to a significant decline of approximately 48% in share price during after-hours trading [1][1]. Group 2: Investor Information - Investors who purchased Grail securities and suffered losses are encouraged to join the investigation without any cost or obligation [1]. - Contact information for inquiries includes Jim Baker at (619) 814-4471 or via email [1]. Group 3: Johnson Fistel Overview - Johnson Fistel, PLLP is a nationally recognized law firm specializing in shareholder rights and securities class action lawsuits, with a history of recovering approximately $90.725 million for clients [1][1]. - The firm has been ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services in 2024, marking its eighth recognition as a top plaintiffs' securities law firm in the U.S. [1].

Core Viewpoint - Kahn Swick & Foti, LLC is investigating the proposed sale of Masimo Corporation to Danaher Corporation, focusing on the adequacy of the $180.00 cash offer per share for Masimo shareholders [1] Company Overview - Masimo Corporation is set to be acquired by Danaher Corporation under a proposed transaction where shareholders will receive $180.00 in cash for each share they own [1] Investigation Details - The law firm Kahn Swick & Foti, LLC, led by former Louisiana Attorney General Charles C. Foti, Jr., is assessing whether the sale price adequately reflects the value of Masimo Corporation and the process leading to this valuation [1]

Core Viewpoint - Klarna Group plc is facing a securities fraud class action lawsuit due to significant losses incurred by investors following its IPO and subsequent financial disclosures that revealed a substantial increase in credit loss provisions [1] Group 1: Company Overview - Klarna Group plc conducted its IPO on September 10, 2025, selling 34.3 million shares at $40 per share [1] - Following the IPO, the company's stock price has significantly declined, closing at $31.63 per share on November 18, 2025, after a 9.3% drop due to negative financial results [1] Group 2: Financial Performance - In its third quarter 2025 financial results, Klarna reported a 39% increase in its provision for credit losses, attributed to changes in market and product mix, particularly an increased share of the U.S. market in its Gross Merchandise Volume (GMV) [1] Group 3: Legal Proceedings - The class action lawsuit alleges that Klarna's management made materially false and misleading statements regarding the company's business and operations, particularly underestimating the risk of increased loss reserves shortly after the IPO [1] - Investors who acquired Klarna securities in connection with the IPO have until February 20, 2026, to seek appointment as lead plaintiffs in the lawsuit [1]